A small UK chip company just locked in a multi-year deal to supply the brain-implant silicon for one of the most advanced clinical-stage depression therapies in the US. MintNeuro, an Imperial College London spinout building miniaturised neural sensing and stimulation integrated circuits, will provide its chips to Motif Neurotech across pre-clinical, early clinical, and pivotal trial phases of Motif’s DOT depression implant. The agreement was announced on 6 May 2026, two weeks after Motif received FDA Investigational Device Exemption clearance to begin its first human trial in treatment-resistant depression.

How the deal is structured

The supply agreement is multi-year and covers the full clinical development arc. MintNeuro’s sensing chip is already integrated into Motif’s pre-clinical work today. The roadmap aligns future MintNeuro chip generations with Motif’s clinical milestones, moving from sensing-only capability today to integrated sensing-plus-stimulation chips as Motif’s programme progresses toward the pivotal trial phase. The companies described the relationship as having progressed from joint system architecture to active hardware validation.

The Brain Mesh background

MintNeuro and Motif are already collaborators through Brain Mesh, a £4.7 million joint project developing distributed networks of ultra-small wireless neural implants for mental health applications. The 6 May supply deal converts that joint research relationship into a commercial supply arrangement, with MintNeuro becoming Motif’s contract silicon supplier rather than a co-research partner.

Where Motif sits

Motif Neurotech’s DOT device is a miniaturised brain implant roughly the size of a blueberry, designed to deliver targeted electrical stimulation for treatment-resistant depression in a 20-minute outpatient procedure. Motif is a Houston-based Rice University spinout incubated by the Rice Biotech Launch Pad, with co-founders at Baylor College of Medicine and UTHealth Houston. The FDA’s Investigational Device Exemption clearance, covered in Inside BCI’s 27 April report, made Motif the fastest implantable brain-device company to move from founding to IDE approval with a novel device. Treatment-resistant depression affects roughly 30% of major depressive disorder patients, where standard pharmacotherapy and psychotherapy have failed to produce remission.

Where MintNeuro sits

MintNeuro is a 2022 spinout from Imperial College London’s Next Generation Neural Interfaces Lab, founded by Dorian Haci (CEO), Tim Constandinou (CTO), and Andrew Jackson (CSO). The company’s core technology is ultra-low-power implantable chip design, built on more than two decades of Imperial research. MintNeuro raised £1 million in seed funding in late 2024 and is one of the few European chip designers focused specifically on miniaturised neural implant silicon at scale.

What this signals about the BCI supply chain

The deal sits inside a broader pattern the brain-implant industry is now visibly building toward. The early Neuralink template was full-stack vertical integration: design the implant, build the chip, fund the trial, run the surgical robot, develop the software in-house. The pattern emerging across 2026 is silicon-supplier-plus-clinical-sponsor, closer to how pharmaceutical and traditional medical-device companies build clinical pipelines on top of specialised manufacturing infrastructure.

The same shape is visible elsewhere this year. Precision Neuroscience announced a partnership with Medtronic on 12 January 2026 to integrate its Layer 7 cortical interface with Medtronic’s StealthStation surgical navigation platform, rather than build neuro-navigation in-house. Axoft closed a $55 million Series A in April 2026 with C.P. Group Innovation as lead, using a Chinese commercial partner to execute first-in-human work in Shanghai while Axoft itself focused on the device design. The MintNeuro–Motif deal extends the pattern one layer further down, into the silicon itself.

What to watch

The next visible signals are Motif’s first clinical readouts from the IDE trial, which will indicate whether the MintNeuro-supplied sensing performs to specification in human implant conditions. Beyond Motif, the supply-chain pattern is the trend to watch. If more US BCI clinical-stage developers move to contract silicon suppliers rather than build chips in-house, the brain-implant industry will look structurally more like the medical-device sector and less like consumer electronics. That changes which companies need to be valued for chip design capability and which need to be valued for the clinical pipeline alone.

Sources

• MintNeuro and Motif Neurotech Partner to Advance Miniature Brain-Computer Interface Therapy for Mental Health (PRNewswire, 6 May 2026)
• MintNeuro and Motif Neurotech collaborate for mental health therapies (Medical Device Network)
• MintNeuro, Motif Neurotech collab on BCI for mental health (MassDevice)
• Brain-computer interface based on Rice research wins FDA approval for first clinical trial (Rice News)
• £1m to advance MintNeuro’s transformative semiconductor tech for neural implants (Imperial College London News)
• Precision Neuroscience and Medtronic Partner to Integrate Layer 7 Brain-Computer Interface with Medtronic Neurosurgical Platform (GlobeNewswire, 12 January 2026)